Eli Health, a pioneer in real-time hormone monitoring, has closed a $12 million USD Series A funding round led by BDC Capital’s Thrive Venture Fund, bringing its total funding to $20 million USD. This latest investment will accelerate the launch of Eli’s flagship innovation—the Hormometer™, the world’s first instant hormone test delivering results from saliva to app in minutes.
At a time when over 60% of adults experience symptoms linked to hormone imbalances, Eli Health is addressing a long-ignored need in personal wellness. Hormones, especially cortisol—the stress hormone—are fundamental to how we function, feel, and age. However, traditional lab tests often miss daily hormone fluctuations, making it difficult to manage symptoms or adapt lifestyles accordingly. Eli Health bridges this gap by enabling real-time, on-demand hormone tracking anytime, anywhere.
The Hormometer™ launches with cortisol as its first tracked hormone, with progesterone coming next. Subscription plans begin at $8/test for an annual commitment, with flexible pricing options also available. Through its companion mobile app, users receive instant results, personalized hormone trends, and AI-powered recommendations—all without the need for labs or sample shipments.
The device has completed third-party validations, is FDA registered, and is manufactured in-house, positioning Eli Health to meet growing demand. The platform’s technology stack is supported by 12+ patent-pending innovations across biochemistry, microfluidics, AI, and endocrinology, and has been recognized with CES’ 2025 “Best of Innovation in Digital Health” award.
With the new funding, Eli Health will scale production, expand its biomarker library, and strengthen its role in personalized health. A private beta is currently underway.
“Until now, hormone data has been too expensive, slow, and inaccessible,” said Marina Pavlovic Rivas, co-founder and CEO. “We’ve created a real-time interface to the human body—making hormone tracking as easy as brushing your teeth.”
In addition to BDC Capital, investors include Muse Capital, TELUS Global Ventures, Accelia Capital, Rocana Ventures, Foreground Capital, and others. Their collective support affirms Eli Health’s mission to transform hormonal health from invisible and episodic to accessible and continuous—redefining the future of personalized wellness.